EXCLUSIVE: Adial Pharmaceuticals' Lead Drug Secures Key US Patent For Alcohol Dependence Based on Expanded Genotype Combinations
EXCLUSIVE: Adial Pharmaceuticals' Lead Drug Secures Key US Patent For Alcohol Dependence Based on Expanded Genotype Combinations
These genotype combinations include the HTR3A, HTR3B, and SLC6A4 receptor sites, which are expected to play an important role in the company's precision medicine approach to treating addiction and may support the expansion of its pipeline.On Tuesday, Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) announced that patent number 12150931 was issued by the United States Patent and Trademark Office on November 26, expanding the company's intellectual property coverage.
在週二，adial pharmaceuticals公司（納斯達克：ADIL）宣佈，專利號12150931於11月26日由美國專利和商標局頒發，擴大了公司的知識產權保護範圍。
The patent covers a broader range of genotype combinations identified by the company's proprietary genetic diagnostic for targeted treatment of alcohol use disorder (AUD) with AD04, the company's lead investigational new drug product.
該專利涵蓋了公司專有基因診斷識別的更廣泛的基因型組合，用於針對AUD的靶向治療，使用的是公司主要的研究新藥AD04。
Also Read: EXCLUSIVE: Adial Pharmaceuticals Advances Regulatory Strategy For Companion Diagnostic Genetic Test For Its Lead Program For Alcohol Use Disorder
另請閱讀：獨家：adial pharmaceuticals爲其酒精使用障礙主要項目的伴隨診斷基因檢測推進監管策略
These genotype combinations include the HTR3A, HTR3B, and SLC6A4 receptor sites, which are expected to play an important role in the company's precision medicine approach to treating addiction and may support the expansion of its pipeline.
這些基因型組合包括HTR3A、HTR30億和SLC6A4受體位點，這些位點預計將在公司的精準醫療方法中發揮重要作用，並可能支持其產品管線的擴展。
"This patent significantly enhances our intellectual property portfolio, providing us with greater flexibility and protection as we advance AD04 toward commercialization," said Cary Claiborne, CEO of Adial Pharmaceuticals.
adial pharmaceuticals的首席執行官Cary Claiborne表示：「這項專利顯著增強了我們的知識產權組合，爲我們推進AD04商業化提供了更大的靈活性和保護。」
The company says it has expanded patent coverage for AD04, focusing on its use in personalized medicine. This new patent strengthens the company's strategy to protect AD04 for treating AUD by covering all genotype combinations identified in our clinical program, ensuring intellectual property protection through 2031.
公司表示已擴展AD04的專利覆蓋，專注於其在個性化醫療中的應用。這個新專利加強了公司保護AD04治療AUD的策略，通過覆蓋我們臨床項目中識別的所有基因型組合，確保知識產權保護直至2031年。
In November, Adial Pharmaceuticals completed a pharmacokinetics (PK) study of AD04 for Alcohol Use Disorder in heavy drinking patients (defined as less than ten drinks/drinking day).
在11月，adial pharmaceuticals完成了對重度飲酒患者（定義爲每天少於十杯酒）的AD04的藥代動力學（PK）研究。
The results showed that, due to the lower dose, AD04 0.33mg delivered lower ondansetron PK exposure than the marketed reference standard ondansetron 4mg tablet; ondansetron pharmacokinetic exposure increased in proportion to dose across a 3–fold AD04 dose range; and AD04 could be taken in fed or fasted states.
結果顯示，由於低劑量，AD04 0.33mg的ondansetron藥代動力學暴露低於市場參考標準ondansetron 4mg片劑；ondansetron的藥代動力學暴露與劑量成正比，跨越3倍AD04劑量區間；且AD04可在進食或禁食狀態下服用。
Price Action: At last check on Tuesday, ADIL stock was down 0.93% at $1.06 during the premarket session.
價格走勢：截至週二收盤，ADIL股票在盤前交易中下跌了0.93%，報1.06美元。
- Generative AI-Backed Cybersecurity Stocks Cloudflare, Okta Have Near-Term Upside: Analyst
- 生成式人工智能支持的網絡安全概念股票cloudflare、okta在短期內有上漲潛力：分析師
譯文內容由第三人軟體翻譯。
